LONG-TERM SAFETY AND EFFICACY OF SB4 (ETANERCEPT BIOSIMILAR) IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON BETWEEN CONTINUING SB4 AND SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO SB4

被引:13
|
作者
Emery, P. [1 ]
Vencovsky, J. [2 ]
Sylwestrzak, A. [3 ]
Leszczynski, P. [4 ]
Porawska, W. [5 ]
Stasiuk, B. [6 ]
Hilt, J. [7 ]
Mosterova, Z. [8 ]
Cheong, S. Y. [9 ]
Ghil, J. [10 ]
机构
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[2] Inst Rheumatol, Prague, Czech Republic
[3] NZOZ Med Pro Familia Sp ZOO, Warsaw, Poland
[4] Poznan Univ Med Sci, Poznan, Poland
[5] Poznanski Osrodek Medyczny NOVAMED, Pultusk, Poland
[6] Medicome Sp ZOO, Oswiecim, Poland
[7] Ctr Terapii Wspolczesnej JM Jasnorzewska Sp Koman, Bialystok, Poland
[8] Revmactr MU Dr Mostera Sro, Brno, Czech Republic
[9] Samsung Bioepis Co Ltd, Suwon, South Korea
[10] Samsung Bioepis Co Ltd, Incheon, South Korea
关键词
D O I
10.1136/annrheumdis-2016-eular.3137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
THU0150
引用
收藏
页码:236 / 236
页数:1
相关论文
共 50 条
  • [1] Comparison between Continuing SB4 (Etanercept Biosimilar) and Switching from Reference Etanercept to SB4: Long-Term Safety and Efficacy of SB4 from a Phase III Study
    Emery, Paul
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Stasiuk, Barbara
    Hilt, Joanna
    Mosterova, Zdenka
    Cheong, Soo-Yeon
    Ghil, Jeehoon
    [J]. JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 877 - 878
  • [2] Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
    Emery, Paul
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Stasiuk, Barbara
    Hilt, Joanna
    Mosterova, Zdenka
    Cheong, Yeon
    Ghil, Jeehoon
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (12) : 1986 - 1991
  • [3] Additional Efficacy Results of SB4 (Etanercept Biosimilar) up to Week 100: Comparison Between Continuing SB4 and Switching from Reference Etanercept (Enbrel®) to SB4
    Emery, Paul
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Stasiuk, Barbara
    Hilt, Joanna
    Mosterova, Zdenka
    Cheong, Soo Yeon
    Ghil, Jeehoon
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis
    Young Hee Rho
    Anna Rychlewska-Hańczewska
    Beata Śliwowska
    Tae Hyung Kim
    [J]. Advances in Therapy, 2019, 36 : 2287 - 2295
  • [5] Clinical experience with the etanercept biosimilar SB4 in psoriatic patients
    Pescitelli, L.
    Lazzeri, L.
    Di Cesare, A.
    Tripo, L.
    Ricceri, F.
    Prignano, F.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 9 - 12
  • [6] Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis
    Rho, Young Hee
    Rychlewska-Hanczewska, Anna
    Sliwowska, Beata
    Kim, Tae Hyung
    [J]. ADVANCES IN THERAPY, 2019, 36 (09) : 2287 - 2295
  • [7] Clinical experience with the etanercept biosimilar SB4 in psoriatic patients
    L. Pescitelli
    L. Lazzeri
    A. Di Cesare
    L. Tripo
    F. Ricceri
    F. Prignano
    [J]. International Journal of Clinical Pharmacy, 2019, 41 : 9 - 12
  • [8] OUTCOMES AFTER SWITCHING FROM ETANERCEPT ORIGINATOR TO ITS BIOSIMILAR (SB4) FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Rokad, Aasiyah
    Kearsley-Fleet, Lianne
    Watson, Kath
    Lunt, Mark
    Hyrich, Kimme L.
    [J]. RHEUMATOLOGY, 2022, 61 : I7 - U568
  • [9] SB4 (Benepali®; an etanercept biosimilar): a profile of its use
    Lyseng-Williamson K.A.
    McKeage K.
    [J]. Drugs & Therapy Perspectives, 2018, 34 (2) : 50 - 61
  • [10] Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo
    Emery, Paul
    Vencovsky, Jiri
    Ghil, Jeehoon
    Cheong, Soo Yeon
    Rho, Young Hee
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (10) : E65 - E65